Quantcast
Last updated on April 16, 2014 at 17:34 EDT

GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte’s 2011 Technology Fast 500(TM)

October 24, 2011

ORLANDO, Fla., Oct. 24, 2011 /PRNewswire/ — GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today announced that it ranked number 33 on Technology Fast 500(TM), Deloitte’s ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. GeneLink grew 4,363 percent during the period 2006-2010.

GeneLink’s chief executive officer, Dr. Bernard L. Kasten, Jr., credits the Company’s leading genetic science and its proprietary genetic assessments and personalized health products for the Company’s dramatic revenue growth. Dr. Kasten said, “We are proud that Deloitte has recognized our remarkable growth for the third consecutive year. We at GeneLink have spent the current year developing and formalizing additional marketing relationships, some of which have been announced, and enhancing our scientific resources, manufacturing capabilities and infrastructure, which we anticipate will enable us to sustain this impressive rate of growth.”

“GeneLink, like all 2011 Technology Fast 500(TM) companies, has excelled in fostering innovation and channeling it into spectacular growth – against the backdrop of one of the most challenging economies in history,” said Eric Openshaw, vice chairman and U.S. technology, media and telecommunications leader. Deloitte L.P. “Deloitte commends GeneLink for this remarkable accomplishment.”

“We are pleased to honor GeneLink as a 2011 Technology Fast 500 company,” said Mark Jensen, managing partner, technology and venture capital services, Deloitte & Touch LLP. “As one of the fastest growing tech companies in North America, GeneLink has demonstrated excellence in technological innovation, entrepreneurship and rapid growth.”

GeneLink previously ranked number 92 as a Technology Fast 500(TM) award winner for 2008 and number 66 for 2009.

About Deloitte’s 2011 Technology Fast 500(TM)

Technology Fast 500, which was conducted by Deloitte & Touche, LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About GeneLink BioSciences, Inc.:

GeneLink Biosciences, Inc. (www.genelinkbio.com) is a 17-year-old leading biosciences company specializing in consumer genomics. GeneLink’s patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer’s wellness needs.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE GeneLink BioSciences, Inc.


Source: PR Newswire